Transparency is a fundamental principle of the operations of the CBER Surveillance Program including the BEST Initiative, Sentinel System, CMS collaboration, and others. Knowledge acquired from the surveillance activities is placed in the public domain. To accomplish this aim, information concerning surveillance activities will be made available on the BEST website and other locations when appropriate.
Most Recent Publications & Presentations Assessments
An FDA-CBER Update on Surveillance, Epidemiology and Risk Management Approaches for Biologics
DIA PV and Risk Management Strategies Conference
Biologics Effectiveness and Safety (BEST) Initiative: Sentinel Public Meeting 2019
Sentinel Public Meeting 2019
Biologics Effectiveness and Safety (BEST) Initiative: First Year
OHDSI Symposium 2018